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**Abstract**

Ketamine has been demonstrated to exert rapid and sustained antidepressant effects for patients with depression including treatment-resistant depression (TRD). However, a number of adverse effects preclude routine use of ketamine, thus, alternatives to ketamine are needed. Metabotropic glutamate (mGlu) 2/3 receptor antagonists have been demonstrated antidepressant effects in animal models, and some of the mechanisms underlying antidepressant effects are shared by ketamine, which raise the possibility that mGlu2/3 receptor antagonists could be an alternative to ketamine. Therefore, synaptic and neural mechanisms of mGku2/3 receptor antagonists were investigated and compared with those of ketamine.

Systemic administration of mGlu2/3 receptor antagonists and ketamine exhibited rapid and sustained antidepressant effects in animal models, including those refractory to current medications. Antidepressant effects of mGlu2/3 receptor antagonists and ketamine were attenuated by NBQX (an AMPA receptor antagonist), K252a (a TrkB inhibitor) and rapamycin (an mTOR signaling inhibitor), suggesting that mGlu2/3 receptor antagonists and ketamine share synaptic mechanisms that both compounds may increase synaptic formation, which is underpinned by the reports that both compounds increase synaptic protein synthesis. Interestingly, local injection of LY341495 or ketamine into the mPFC exerted antidepressant effects in the forced swimming test, and antidepressant effects were attenuated by local injection of NBQX into the mPFC, indicating that both an mGlu2/3 receptor antagonist and ketamine exert the effects through AMPA receptor stimulation in the mPFC. In addition, we found that depletion of serotonin blocked antidepressant effects induced by local injection of LY341495 or ketamine into the mPFC. We also found that both compounds increased the c-Fos expression in the serotonin neurons in the dorsal raphe nucleus (DRN), which was blocked by local injection of NBQX into the mPFC, suggesting that both compounds may activate subsets of serotonin neurons in the DRN regulated by AMPA receptor stimulation in the mPFC.

These studies revealed that mGlu2/3 receptor antagonists exhibited similar antidepressant profiles with ketamine in animal models in that they exerted rapid and sustained effects and were effective in animal models refractory to current medications. Moreover, mGlu2/3 receptor antagonists may share mechanisms underlying antidepressant effects with ketamine at both synaptic and neural levels. Therefore, mGlu2/3 receptor antagonists may be useful as an alternative approach to treating patients with TRD. Other agents including GLYX-13 and GluN2B antagonists which could be alternatives to ketamine will also be briefly discussed.
